News

Researchers have targeted cancer’s ability to develop resistance to a single drug by launching a multi-pronged attack. The team has combined a gene-targeted drug, a cancer-bursting virus and a drug that removes the immune system’s brake pedal to combat thyroid cancer using a mouse model.

The University of Oxford and pharmaceutical company AstraZeneca have published a peer-reviewed analysis of Phase III trials of the COVID-19 vaccine ChAdOx1 nCoV-2019 in the Lancet. The publication confirms that ChAdOx1 has an efficacy of 70.4% across two dose regimens, as previously announced.

A research team has designed a new technology using synthetic llama antibodies to prevent specific proteins from being destroyed inside cells. The approach could be used to treat several diseases.

Some drugs consist of peptides acting on their protein targets. To make them more efficient and stable, scientists have found a way to replace crucial segments of these peptides with ureido units. These "fake" peptides could help researchers design better, more effective drugs that are less likely to be attacked by proteolytic enzymes.

Vanderbilt University Medical Center researchers have discovered individuals with type 1 and type 2 diabetes infected with COVID-19 are three times more likely to have a severe illness or require hospitalization compared with people without diabetes.

Scientists have studied how antibodies and immune cells protect the body from SARS-CoV-2 in rhesus macaques.

New research investigates how some benefits of physical exercise can be achieved through gene therapy and medicines.

A new cancer therapy, known as CAR T-cell therapy, has shown promising results when administered to patients suffering from non-Hodgkin lymphoma in a recent clinical trial.

Subcutaneous injection of the drug teclistamab was shown to be safe and elicit responses in nearly 75 percent of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional Phase I study being presented at the 62nd ASH Annual Meeting and Exposition.

A genetically engineered T cell has been found to effectively target and attack pathogenic cells that cause type one diabetes.